Patent ID: 8026231
Filing Date: 2011-09-27
Classification: A61P,C07C,C07D

Abstract:
1. A method for the treatment, regression, and/or hindering of further development of prostate cancer which is resistant to the induction of apoptosis, wherein said resistance is due to the presence in cancer cells of the bcl 2 gene, or the MDR gene, or the BCL-X L gene, or the enzyme ALDH, said method comprising administering to a subject in need of such treatment at least one compound selected from the group consisting of: S-methyl 4-dimethylamino-4-methyl-2-pentynethioate; S-methyl 4-di-n-propylamino-4-methyl-2-pentynethioate; S-methyl 4-methyl-4-pyrrolidin-1-yl-2-pentynethioate; and S-methyl 4-methyl-4-morpholin-4-yl-2-pentynethioate.